bullish
CureVac May Supply ~225M of Potential COVID-19 Vaccine Doses. A Big Win Over Moderna and BioNTech
334 Views21 Aug 2020 03:05
Today German coronavirus vaccine developer CureVac has concluded an Advanced Purchase Agreement (APA) to provide all EU Member States with up to...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Rising
Andrei Zakharov
Covering IPOs, Healthcare and Technology Stocks
Price Chart(Sign Up to Access)
- CureVac Stock May Surge Another 20-30% Under New Bull-Case Scenario23 Nov 2020
- Success of Moderna’s COVID-19 Vaccine May Give a Boost to Stocks of Messenger RNA Companies13 Nov 2020
- Expecting First Results From Phase 1 Clinical Trials Of COVID-19 Vaccine In October28 Sep 2020
- How High Can CureVac Stock Go After Blockbuster IPO? We Update Bull Case Scenario to $80 Per Share17 Aug 2020
- CureVac IPO. Beating Rivals to Secure a COVID-19 Vaccine Based on MRNA Technology14 Aug 2020
x